PatientPoint, a patient engagement solutions provider, has collaborated with digital health company Antidote Technologies to improve clinical trial recruitment using point-of-care patient engagement tools.
As part of the alliance, PatientPoint will direct patients and providers at more than 7,300 primary care and subspecialty practices in the US to Antidote’s digital clinical trial search tool called Antidote Match.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Antidote’s technology, which involves a short questionnaire, uses medical ontologies to provide patients with an easy approach to find and connect with medical research.
Currently, the technology powers clinical trials search on more than 250 partner websites.
Antidote Technologies CEO Laurent Schockmel said: “Partnering with PatientPoint is a natural extension of our mission to accelerate breakthroughs in potentially life-saving treatments by bridging the gap between medical research and the people who need it.
“By extending our reach to the point of care, we will meet patients and their trusted providers where they are and when they are primed to act. This will drive trial enrolment and ultimately get next-generation treatments to patients who need them sooner.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe partners intend to reach out to patients and providers in waiting rooms, exam rooms and the physician back office. They aim to drive doctor-patient discussion and in turn trial participation rates.
PatientPoint founder and CEO Mike Collette said: “When research comes to a standstill, so does the development of tomorrow’s therapies that patients desperately need today.
“Our partnership with Antidote is designed to help reverse that trend by harnessing the influence of the physician and the power of patient-provider discussions to drive interest and enrolment in clinical trials.”
